Low Nirmatrelvir/Ritonavir Use Among Patients With Rheumatoid Arthritis: A Signal of Concern.

Timothy S H Kwok Bindee Kuriya Lihi EderVivian AghanyaJodi M GatleyJessica Widdifield

Published in: The Journal of rheumatology (2023)

Individuals with rheumatoid arthritis (RA) may be at increased risk of severe coronavirus disease 2019 (COVID-19) outcomes. 1 Nirmatrelvir/ritonavir has been shown to reduce the risk for hospitalization and death among patients with COVID-19 at risk for progression to severe disease. 2 .

Keyphrases

coronavirus disease
rheumatoid arthritis
early onset
disease activity
sars cov
respiratory syndrome coronavirus
antiretroviral therapy
interstitial lung disease
type diabetes
systemic lupus erythematosus
adipose tissue
idiopathic pulmonary fibrosis